OMIDRIA: payments to doctors
Payments that named OMIDRIA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.3M
- Providers
- 5,201
- Transactions
- 11,420
- Average per transaction
- $112
The per-transaction average — $112 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5,201 providers the average total is $245, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Omeros Corporation | $863,180 | 67.8% |
| Rayner Intraocular Lenses Limited | $410,611 | 32.2% |